SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 12/17/2017 11:31:53 PM - Followers: 735 - Board type: Free - Posts Today: 1

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
PostSubject
#208548  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 12/16/17 03:20:14 PM
#207895  Sticky Note Due diligence: Innovation Pharmaceuticals Inc. (IPIX) BooDog 12/13/17 06:48:21 AM
#207221  Sticky Note Re B-OM Ph2 topline: A Lead-Off Stand-Up Double slcimmuno 12/11/17 08:36:46 AM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#208705   Under the "Disclaimer and Privacy Policy" for Sierra Blues44 12/18/17 12:27:44 AM
#208704   We would absolutely prefer stock then declare a groton68 12/17/17 11:31:53 PM
#208703   Pfizer might prefer cash but stock for stock aculeus 12/17/17 11:28:08 PM
#208702   Google “Case Report Form Clinical trials” F1ash 12/17/17 10:54:41 PM
#208701   Google “Case Report Form Clinical trials” and you Yooper61 12/17/17 10:43:07 PM
#208700   Approximately 57.1% of the subjects in the trial georgejjl 12/17/17 10:42:40 PM
#208699   I’m comparing apples to apples. Extreem 1&2 Yooper61 12/17/17 10:35:00 PM
#208698   So Otezla Extreem 1 & 2 resulted Yooper61 12/17/17 10:17:46 PM
#208697   Here, let me fix that for you: LilKahuna 12/17/17 10:09:47 PM
#208696   Probably sometime in January. It's really a septmike09 12/17/17 10:01:40 PM
#208695   When do you foresee results being released? AKBrakeman 12/17/17 09:44:45 PM
#208694   I am not seeing a buyout anytime soon. septmike09 12/17/17 09:00:29 PM
#208693   New Investors heads up->IPIX presenting@BiotechShowcase2018 http://www.ebdgrou Matagordaville 12/17/17 08:58:09 PM
#208692   Unless I'm not aware of the current events AKBrakeman 12/17/17 08:16:21 PM
#208691   Hey georgie.....I know now that your completely FOS tryz 12/17/17 07:34:00 PM
#208690   George. You’re setting up for failure. None of groton68 12/17/17 07:33:23 PM
#208689   Possible Brilacidin OM news this week!!! georgejjl 12/17/17 07:31:53 PM
#208688   Possible buyout offer this week!!! georgejjl 12/17/17 07:29:57 PM
#208687   Possible partnership news this week!!! georgejjl 12/17/17 07:25:23 PM
#208686   Any possible news this week? snayeman 12/17/17 07:16:42 PM
#208684   was responding to your post about K To infinity and beyond! 12/17/17 06:17:20 PM
#208683   Again, I believe he does get such reports. loanranger 12/17/17 05:06:48 PM
#208682   Pfizer could be preparing to buy all of IPIX georgejjl 12/17/17 04:43:43 PM
#208681   yes but the trial with another agent woulda To infinity and beyond! 12/17/17 04:22:14 PM
#208680   As a successful p53 activator it could become Blue Fin 12/17/17 04:16:36 PM
#208679   I think that is the most likely move petemantx 12/17/17 03:43:10 PM
#208678   It’s very brave of you to rather accepting sox040713 12/17/17 03:25:14 PM
#208677   Pfizer has so much cash. They would prefer groton68 12/17/17 03:18:14 PM
#208676   I meant $5 plus! Expecting big things from MAXMDUD 12/17/17 03:05:01 PM
#208675   My premise was based on a full sale Blue Fin 12/17/17 02:52:45 PM
#208674   I believe Leo receives patient case reports as sox040713 12/17/17 02:28:44 PM
#208673   How would that work (stock trade) if Pfizer petemantx 12/17/17 02:08:40 PM
#208672   Kevetrin: The primary phase II trial is to Blue Fin 12/17/17 01:29:35 PM
#208671   Dr. ARTHUR P. BERTOLINO, MD, PHD, MBA and Pfizer georgejjl 12/17/17 01:27:26 PM
#208670   Sierra, now that's one we haven't seen in BooDog 12/17/17 01:21:13 PM
#208669   Leo’s original plan was to run a Phase sox040713 12/17/17 01:17:26 PM
#208668   Rumor regarding Innovation Pharmaceuticals and Pfizer georgejjl 12/17/17 12:53:33 PM
#208667   Chart says 1.20 soon septmike09 12/17/17 12:32:34 PM
#208666   It lasted for not more than 3 days Amatuer17 12/17/17 12:19:52 PM
#208665   Extended release is one way to solve the sox040713 12/17/17 12:05:00 PM
#208664   The market reaction on that day (1/20/2015) was sox040713 12/17/17 11:55:45 AM
#208663   Site/Clinical Monitoring - The sponsor or a TheHound 12/17/17 11:20:12 AM
#208662   Well put With very short life - giving IV Amatuer17 12/17/17 11:16:07 AM
#208661   Where that news disappeared? Company has not mentioned or Amatuer17 12/17/17 11:13:02 AM
#208660   Chart say Kevetrin Recist data. Imo DaubersUP 12/17/17 11:12:21 AM
#208659   Keep being negative groton68 12/17/17 11:12:19 AM
#208658   aha- there you have it, the single best To infinity and beyond! 12/17/17 11:12:19 AM
#208657   chart says .58 soon MXAMDUD 12/17/17 10:54:24 AM
#208656   and create shAREHOLDER VALUE. WHICH he has not MXAMDUD 12/17/17 10:53:25 AM
#208655   One of the jobs of CEO’s is to groton68 12/17/17 10:24:51 AM
PostSubject